Saluting Innovation at Edwards Lifesciences for over 50 years of continued innovation, dating back to 1958 when Miles Edwards teamed with Dr. Albert Starr to develop the world’s first replacement heart valve. An industry leader in research and development investment, Edwards Lifesciences recently received U.S. Food and Drug Administration (FDA) approval for its ClearSight hemodynamic monitoring system. The ClearSight monitoring system offers the most advanced non-invasive approach to monitoring blood movement in the body. This approach expands the potential patient population to include the obese, the elderly, and potentially astronauts in space. The ClearSight monitoring system contributes to lower healthcare costs, shorter hospital stays, and reduced post-surgery complications. We salute Edwards Lifesciences for developing an innovative method to monitoring hemodynamic information with their ClearSight system and a continued commitment to medical device innovation.